subscribeSubscribe
FDA Confirms Paragraph IV Patent Litigation for Abacavir Sulfate, Dolutegravir and Lamivudine Tablets

FDA Confirms Paragraph IV Patent Litigation for Abacavir Sulfate, Dolutegravir and Lamivudine Tablets

FDA
15 Jun 2023
Share Share
Laurus Labs Generic Abacavir Sulfate Receives Approval in the U.S.

Laurus Labs Generic Abacavir Sulfate Receives Approval in the U.S.
FDA
25 Jul 2022
Share Share
The Food and Drug Administration approved revisions to the TRIUMEQ

The Food and Drug Administration approved revisions to the TRIUMEQ
FDA
12 Mar 2021
Share Share
5 FDA-approved antivirals could target COVID-19: study

5 FDA-approved antivirals could target COVID-19: study
A. Weintraub FIERCE BIOTECH
02 Jul 2020
Share Share
New Paragraph IV Certifications as of April 7, 2020

New Paragraph IV Certifications as of April 7, 2020
FDA
08 Apr 2020
Share Share
ViiV Healthcare Submits Supplemental New Drug Application to US FDA

ViiV Healthcare Submits Supplemental New Drug Application to US FDA
BUSINESSWIRE
16 Oct 2019
Share Share
ViiV’s Dovato wins US approval PRV, empowering GSK to muscle Gilead’s HIV empire

ViiV’s Dovato wins US approval PRV, empowering GSK to muscle Gilead’s HIV empire
Natalie Grover ENDPTS
10 Apr 2019
Share Share
List of Paragraph IV Patent Certifications Feb-12, 2019

List of Paragraph IV Patent Certifications Feb-12, 2019
FDA
13 Feb 2019
Share Share
Aurobindo Pharma` Generic Abacavir Sulfate; Lamivudine Receives Approval in US

Aurobindo Pharma` Generic Abacavir Sulfate; Lamivudine Receives Approval in US
FDA
22 Nov 2018
Share Share
Aurobindo Pharma Generic Abacavir Sulfate; Lamivudine Receives Approval in US

Aurobindo Pharma Generic Abacavir Sulfate; Lamivudine Receives Approval in US
FDA
16 Nov 2018
Share Share